KR102646581B1 - 신규 화합물 및 그의 치료 용도 - Google Patents

신규 화합물 및 그의 치료 용도 Download PDF

Info

Publication number
KR102646581B1
KR102646581B1 KR1020197032866A KR20197032866A KR102646581B1 KR 102646581 B1 KR102646581 B1 KR 102646581B1 KR 1020197032866 A KR1020197032866 A KR 1020197032866A KR 20197032866 A KR20197032866 A KR 20197032866A KR 102646581 B1 KR102646581 B1 KR 102646581B1
Authority
KR
South Korea
Prior art keywords
formula
antibody
compound
nhco
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197032866A
Other languages
English (en)
Korean (ko)
Other versions
KR20200018402A (ko
Inventor
미카엘 웨스트비
멜라니 글로솝
크리스틴 왓슨
크리스토퍼 픽포드
Original Assignee
센타우리 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센타우리 테라퓨틱스 리미티드 filed Critical 센타우리 테라퓨틱스 리미티드
Publication of KR20200018402A publication Critical patent/KR20200018402A/ko
Application granted granted Critical
Publication of KR102646581B1 publication Critical patent/KR102646581B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197032866A 2017-04-07 2018-04-06 신규 화합물 및 그의 치료 용도 Active KR102646581B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1705686.2A GB201705686D0 (en) 2017-04-07 2017-04-07 Novel compounds and therapeutic uses thereof
GB1705686.2 2017-04-07
PCT/GB2018/050928 WO2018185495A1 (en) 2017-04-07 2018-04-06 Novel compounds and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
KR20200018402A KR20200018402A (ko) 2020-02-19
KR102646581B1 true KR102646581B1 (ko) 2024-03-13

Family

ID=58744828

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032866A Active KR102646581B1 (ko) 2017-04-07 2018-04-06 신규 화합물 및 그의 치료 용도

Country Status (12)

Country Link
US (1) US11766483B2 (cg-RX-API-DMAC7.html)
EP (1) EP3606561B1 (cg-RX-API-DMAC7.html)
JP (2) JP7695773B2 (cg-RX-API-DMAC7.html)
KR (1) KR102646581B1 (cg-RX-API-DMAC7.html)
CN (1) CN110753558B (cg-RX-API-DMAC7.html)
AU (1) AU2018248706B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059018A1 (cg-RX-API-DMAC7.html)
ES (1) ES2954294T3 (cg-RX-API-DMAC7.html)
GB (1) GB201705686D0 (cg-RX-API-DMAC7.html)
IL (1) IL270460B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018185495A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201906580B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン,インコーポレイテッド 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090381A (en) * 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
FR2801305B1 (fr) 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
FI20011664A7 (fi) 2001-08-17 2003-02-18 Carbion Oy Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
EP2322209A3 (en) 2002-08-20 2012-02-01 Glykos Finland Oy Tumor specific oligosaccharide epitopes and use thereof
EP1882684B1 (en) 2005-05-19 2014-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
CN105709237A (zh) * 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
CA2655246A1 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
US9156906B2 (en) 2008-02-26 2015-10-13 The Regents Of The University Of California Glycopeptides and methods of making and using them
EP2283358B1 (en) * 2008-04-29 2015-04-22 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
US9079880B2 (en) * 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
EP2836485B1 (en) * 2012-03-17 2018-01-10 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
US9556167B2 (en) 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
US10973920B2 (en) * 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
GB201517859D0 (en) * 2015-10-08 2015-11-25 Altermune Ltd Novel compounds and therapeutic uses thereof
BR112019004877A2 (pt) * 2016-09-13 2019-06-11 Centauri Therapeutics Limited novos compostos e usos terapêuticos dos mesmos

Also Published As

Publication number Publication date
JP7695773B2 (ja) 2025-06-19
WO2018185495A1 (en) 2018-10-11
CN110753558B (zh) 2023-10-24
IL270460A (cg-RX-API-DMAC7.html) 2019-12-31
EP3606561C0 (en) 2023-08-02
IL270460B1 (en) 2023-05-01
ES2954294T3 (es) 2023-11-21
US20200147236A1 (en) 2020-05-14
US11766483B2 (en) 2023-09-26
AU2018248706A1 (en) 2019-11-07
ZA201906580B (en) 2024-01-31
EP3606561A1 (en) 2020-02-12
KR20200018402A (ko) 2020-02-19
CN110753558A (zh) 2020-02-04
AU2018248706B2 (en) 2022-04-07
GB201705686D0 (en) 2017-05-24
EP3606561B1 (en) 2023-08-02
CA3059018A1 (en) 2018-10-11
JP2023100679A (ja) 2023-07-19
JP2020516613A (ja) 2020-06-11
IL270460B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
US20180258048A1 (en) Benzazepine compounds, conjugates, and uses thereof
US20190336615A1 (en) Tumor targeting conjugates and methods of use thereof
CN113164618A (zh) 用免疫刺激性缀合物治疗疾病的方法和组合物
CA3111580A1 (en) Antibody conjugates of toll-like receptor agonists
JP2024150440A (ja) 化合物及びその治療的使用
JP2023100679A (ja) 新規化合物及びそれらの治療上の使用
CA3049842A1 (en) Construct-peptide compositions and methods of use thereof
US12350348B2 (en) Compounds and therapeutic uses thereof
HK40023976B (en) Novel compounds and therapeutic uses thereof
HK40023976A (en) Novel compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601